周萍, 李昂, 李欣, 陆东哲, 王晓熙, 吴朝晖, 薛迪. 干细胞研究与临床应用的伦理规范与监管[J]. 上海预防医学, 2022, 34(10): 1053-1057. DOI: 10.19428/j.cnki.sjpm.2022.21987
引用本文: 周萍, 李昂, 李欣, 陆东哲, 王晓熙, 吴朝晖, 薛迪. 干细胞研究与临床应用的伦理规范与监管[J]. 上海预防医学, 2022, 34(10): 1053-1057. DOI: 10.19428/j.cnki.sjpm.2022.21987
ZHOU Ping, LI Ang, LI Xin, LU Dongzhe, WANG Xiaoxi, WU Zhaohui, XUE Di. Ethical regulation and supervision of clinical stem cell research and application[J]. Shanghai Journal of Preventive Medicine, 2022, 34(10): 1053-1057. DOI: 10.19428/j.cnki.sjpm.2022.21987
Citation: ZHOU Ping, LI Ang, LI Xin, LU Dongzhe, WANG Xiaoxi, WU Zhaohui, XUE Di. Ethical regulation and supervision of clinical stem cell research and application[J]. Shanghai Journal of Preventive Medicine, 2022, 34(10): 1053-1057. DOI: 10.19428/j.cnki.sjpm.2022.21987

干细胞研究与临床应用的伦理规范与监管

Ethical regulation and supervision of clinical stem cell research and application

  • 摘要: 通过查阅文献,本文分析了国内外对干细胞研究与临床应用的伦理要求以及监管状况;提出我国应及时跟踪干细胞技术的发展,加强前瞻性干细胞伦理研究,使干细胞研究与临床应用遵循国际相关伦理指南、符合我国相关法规;并不断完善我国干细胞产品及其临床应用的监管。

     

    Abstract: In the paper, national and international ethical requirements and supervision on stem cell research and clinical application were analyzed after literature review. It is suggested that the development of stem cell technology should be timely tracked, prospective ethical research related to stem cells should be enhanced, and that stem cell research and clinical translation should comply with relevant international ethical guidelines and national regulations in China. In addition, it is indicated that the oversight of stem cell products and their clinical use will be continuously improved in our country.

     

/

返回文章
返回